Suven granted patents for neurodegenerative drug

Biopharmaceutical company Suven Life Sciences has been granted three product patents for the non-chemical entities for the treatment of neurodegenerative diseases including Alzheimer’s.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Medtech Magnolia fails to revive $2.1m verdict at Fed Circ

9 March 2026 Appeals court upholds lower court’s ruling, clarifying key legal questions concerning patent claims for blood‑testing devices.

Americas

Abbott IP chief: ‘Firms without AI policies scare me’

5 March 2026 The healthcare company’s chief IP counsel is researching how law firms and patent attorneys are using AI tools to inform its own guidelines for external legal providers.

Americas

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

5 March 2026 Moderna settles, agreeing to part with up to $2.25 billion to avoid a trial and secure a licence to continue using the platform underpinning its COVID-19 vaccine.

More features

GSK inks licensing deal for liver disease drug

Arnold & Porter adds tech litigator in San Francisco

Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs

UKIPO extends funding for specialist IP crime unit as counterfeit risks grow

Medtech Magnolia fails to revive $2.1m verdict at Fed Circ

Nomination call: Influential Women in IP list closes ahead of International Women’s Day

Abbott IP chief: ‘Firms without AI policies scare me’

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

Suven granted patents for neurodegenerative drug

More on this story

Editor's picks

Editor's picks

More features